WCIRDC meeting to highlight new cardiometabolic practice recommendations
Click Here to Manage Email Alerts
Experts from the fields of diabetes, cardiorenal and metabolic disease, and obesity will discuss new research and present practice recommendations at the 19th World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease.
The World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC), a multidisciplinary CME program dedicated to management of obesity, diabetes, lipids, hypertension, chronic kidney disease, cardiovascular disease, heart failure, nonalcoholic fatty liver disease (NAFLD) and more, will take place Thursday to Saturday. After going virtual in 2020 due to the COVID-19 pandemic, this year’s congress will have a hybrid format with sessions taking place in-person at the Hilton Universal City in Los Angeles and streamed live online. All of the conference’s sessions will be available on demand for 90 days.
Yehuda Handelsman, MD, FACP, FNLA, FASCP, MACE, medical director and principal investigator of the Metabolic Institute of America in Tarzana, California, and chair of WCIRDC, said the conference is the only meeting of its size dedicated to including presentations on basic science and clinical care for every cardiorenal metabolic specialty. The motto for this year’s meeting is Exploring New Frontiers in Metabolism – Tomorrow’s Clinical Science Today.
“We’re looking to see how the information we’ve gathered this year will impact how we will manage our patients,” Handelsman told Healio. “How will some new information in basic science eventually get its place in future medical care? How does a medication like an SGLT2 inhibitor do what it does? We’re looking both at basic science and translational science.”
WCIRDC brings together professionals, researchers and clinicians from multiple specialties to collaborate on science and management strategies in various areas of cardiometabolic health. The program will include updates on research and management recommendations for obesity, diabetes, insulin resistance, COVID-19, dyslipidemia, NAFLD, atherosclerotic CVD, heart failure, CKD, pediatric cardiorenal metabolic care, hormones, atherosclerosis and more.
Among the highlights at this year’s congress is a first-of-its-kind session where experts from various fields will present multispecialty practices recommendations. The recommendations stem from the Evolving Concepts in the Management of Diabetes and Cardiorenal Metabolic Diseases workshop held in June in Dallas.
“Traditionally, guidelines and practice recommendations have been presented by medical societies,” Handelsman said. “Those medical societies focus on single diseases, but we’re looking today at the cardiorenal metabolic patient who may also have multiple morbidities. What we created is something that everybody — a specialist and a primary care physician — can follow.”
Other featured sessions for this year’s conference:
Pediatric care will be the focus of a session at 2:10 p.m. PST on Thursday. Andrew Moran, MD, MPH, will talk about the benefits of early lipid-lowering interventions to prevent later CVD, Sonia Caprio, MD, will discuss prediabetes and NAFLD in pediatric obesity and Phil Zeitler, MD, PhD, will present findings from the TODAY study on the long-term complications of youth-onset type 2 diabetes.
A joint session with the journal Metabolism will kick off Friday’s agenda at 8:15 a.m. PST. Featuring Dale Abel, MD, PhD, Michael A. Hill, PhD, and Theodoros Kelesidis, MDPhD, the session will focus on insulin action, diabetes and the heart, CV action and therapeutic potential of novel anti-diabetes agents and drug development for cardiometabolic disorders.
At 8:15 a.m. PST on Saturday, a session will feature presentations on the past, present and future of diabetes care. Jay S. Skyler, MD, will look back at the past 100 years since the discovery of insulin. Peter J. Grant, MD, will discuss long-term management of hyperglycemia, and Jennifer Green, MD, will talk about early combination therapy with diabetes and how it affects comorbidities. Julio Rosenstock, MD, will wrap up the session with a presentation on reversing type 2 diabetes from day 1.
The 2021 Gerald Reaven Distinguished Leader in Insulin Resistance Award will be presented to Samuel Klein, MD, on Saturday at 10:35 a.m. PST. Klein’s lecture will focus on why obesity causes type 2 diabetes.
The congress will also include a poster hall, oral abstract presentations and an exhibit hall. Each day will conclude with a summary session where attendees can ask questions to several of that day’s featured presenters.
Healio will provide coverage of the 19th World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease, including reports on the sessions and researcher perspectives. For more information on the conference and registration, visit www.wcir.org.
Collapse
Healio interview
Read more about
Click Here to Manage Email Alerts